Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drive for drugs leads to baby clinical trials

    Nature volume 440, pages 406–407 (2006)Cite this article

    US regulators are moving sharply to ease the early stages of drug development, despite safety concerns. Meredith Wadman reports.

    David Curiel has just spent four years and US$4 million building a state-of-the-art plant to make molecules that could deliver gene therapy to patients.

    Access options

    Rent or Buy article

    Get time limited or full article access on ReadCube.

    from$8.99

    Rent or Buy

    All prices are NET prices.

    Related links

    Related links

    Related links in Nature Research

    London's disastrous drug trial has serious side effects for research

    Earlier drug tests on people could be unsafe, critics warn

    Related external links

    UAB Gene therapy

    FDA exploratory IND guidance

    FDA GMP guidance

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Drive for drugs leads to baby clinical trials. Nature 440, 406–407 (2006). https://doi.org/10.1038/440406a

    Download citation

    Search

    Advanced search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing